Opinion on medicine for use outside EU: Acoziborole Winthrop, acoziborole, Trypanosomiasis, African, 24/02/2026 Positive opinion

Human medicines European public assessment report (EPAR): Jelrix, autologous cartilage-derived articular chondrocytes, in-vitro expanded, Status: Application withdrawn

Human medicines European public assessment report (EPAR): Kygevvi, doxecitine,doxribtimine, Date of authorisation: 26/03/2026, Status: Authorised

Human medicines European public assessment report (EPAR): Prialt, ziconotide, Date of authorisation: 21/02/2005, Revision: 33, Status: Authorised

EU Innovation Network (EU-IN)

Radiopharmaceuticals EU-IN Horizon Scanning Report

PSUSA/00000073/202507

Human medicines European public assessment report (EPAR): Lorviqua, lorlatinib, Date of authorisation: 06/05/2019, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Jorveza, budesonide, Date of authorisation: 08/01/2018, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Bortezomib Hospira, bortezomib, Date of authorisation: 22/07/2016, Revision: 14, Status: Withdrawn